New York, December 08, 2025
Jasveen Sangha, known as the “Ketamine Queen,” pleaded guilty to federal charges related to distributing the deadly ketamine dose that caused actor Matthew Perry’s overdose death in October 2023. The case, unfolding in North Hollywood, exposes a network supplying illicit ketamine beyond medical prescriptions, highlighting grave legal and public health consequences.
Legal Accountability for Ketamine Distribution
Sangha admitted involvement in a coordinated trafficking operation that supplied large quantities of ketamine to Matthew Perry through intermediaries. Prosecutors revealed that just days before Perry’s death, Sangha sold 25 vials of ketamine to facilitate his escalating drug use. Facing up to 65 years in prison, she is the last among five defendants—including medical professionals and others—to plead guilty in connection with the overdose.
Escalation from Medical Use to Illegal Supply
While Perry initially used ketamine legally under medical supervision to treat depression, his dependency intensified, driving him to acquire additional supplies illegally. Friends and legal authorities say his ketamine use spiraled beyond prescribed limits, resulting in Perry turning to Sangha’s network for unauthorized quantities. This shift from therapeutic use to illicit abuse underscores the complexities surrounding certain off-label prescription medications.
Involvement of Others in the Ketamine Network
Perry’s assistant, lacking medical training, reportedly administered ketamine procured via Sangha’s network, further complicating the chain of responsibility. Additionally, a licensed physician was implicated for selling ketamine to the network despite warnings about Perry’s worsening addiction. The investigation also linked Sangha to a prior fatal overdose in 2019, indicating a pattern of supplying dangerous doses.
Broader Implications: Prescription Drug Abuse and Public Safety
The case has renewed scrutiny on the rising non-medical use of ketamine, a drug increasingly misused despite legitimate therapeutic applications. Sangha’s illustrated luxurious social media portrayal contrasted sharply with her involvement in illicit trafficking contributing to a beloved public figure’s death. Authorities and policymakers are now urged to consider stricter regulations and monitoring to prevent similar tragedies.
This unfolding tragedy reveals the blurred lines between medicinal therapies and illegal supply chains, emphasizing the urgent need for enhanced oversight on controlled substances. Sangha’s conviction is a significant step in addressing drug trafficking networks that threaten public health and safety.